L
Lawrence Corey
Researcher at Fred Hutchinson Cancer Research Center
Publications - 816
Citations - 82939
Lawrence Corey is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Herpes simplex virus & Virus. The author has an hindex of 146, co-authored 773 publications receiving 78105 citations. Previous affiliations of Lawrence Corey include Seattle Children's & University of Washington.
Papers
More filters
Journal ArticleDOI
Clinical and epidemiologic features of primary HIV infection.
TL;DR: The events leading to the acquisition of HIV and the initial clinical and diagnostic evaluation of 46 patients with primary HIV infection are summarized.
Journal ArticleDOI
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan Buchbinder,Devan V. Mehrotra,Ann Duerr,Daniel W. Fitzgerald,Robin Mogg,David Li,Peter B. Gilbert,Javier R. Lama,Michael Marmor,Carlos del Rio,M. Juliana McElrath,Danilo R. Casimiro,Keith Gottesdiener,Chodakewitz Jeffrey A,Lawrence Corey,Michael N. Robertson +15 more
TL;DR: This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level and Mechanisms for insufficient efficacy of the vaccine and the increased HIV- 1 infection rates in subgroups of vaccine recipients are being explored.
Journal ArticleDOI
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Kieren A. Marr,Rachel A. Carter,Fulvio Crippa,Anna Wald,Anna Wald,Lawrence Corey,Lawrence Corey +6 more
TL;DR: The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B--resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.
Journal ArticleDOI
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection: A Controlled Trial in Persons with Fewer Than 500 CD4-Positive Cells per Cubic Millimeter
Paul A. Volberding,Stephen W. Lagakos,Matthew A. Koch,David K. Booth,Carla Pettinelli,Maureen Myers,Henry H. Balfour,Richard C. Reichman,John Bartlett,Martin S. Hirsch,Robert L. Murphy,W. David Hardy,Ruy Soeiro,Margaret A. Fischl,John G. Bartlett,Thomas C. Merigan,Newton E. Hyslop,Douglas D. Richman,Fred T. Valentine,Lawrence Corey +19 more
TL;DR: Zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter and additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.
Journal ArticleDOI
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
TL;DR: Risk factor analyses verify previously recognized risk factors (GVHD, receipt of corticosteroids, and neutropenia) and uncover the roles of lymphopenia and viral infections in increasing the incidence of postengraftment IA in the 1990s.